Patents by Inventor Howard R. Levin

Howard R. Levin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10603491
    Abstract: Detection and treatment of disordered breathing is disclosed, with treatment being primarily delivered using electrical stimulation of the diaphragm, either directly or by stimulating appropriate nerves.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: March 31, 2020
    Assignee: Respicardia, Inc.
    Inventors: Mark Gelfand, Howard R. Levin, Andrew Halpert, Antonis Panteleon
  • Publication number: 20200086118
    Abstract: An implantable medical device for treating breathing disorders such as central sleep apnea wherein stimulation is provided to the phrenic never through a transvenous lead system with the stimulation beginning after inspiration to extend the duration of a breath and to hold the diaphragm in a contracted condition.
    Type: Application
    Filed: November 20, 2019
    Publication date: March 19, 2020
    Inventors: Mark Gelfand, Howard R. Levin, Andrew Halpert
  • Patent number: 10518090
    Abstract: An implantable medical device for treating breathing disorders such as central sleep apnea wherein stimulation is provided to the phrenic never through a transvenous lead system with the stimulation beginning after inspiration to extend the duration of a breath and to hold the diaphragm in a contracted condition.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: December 31, 2019
    Assignee: RESPICARDIA, INC.
    Inventors: Mark Gelfand, Howard R. Levin, Andrew Halpert
  • Patent number: 10441356
    Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues. In some embodiments, thermally-induced renal neuromodulation is achieved via delivery of a pulsed thermal therapy.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: October 15, 2019
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Denise Zarins, Andrew Wu, Hanson Gifford, III, Mark Deem, Mark Gelfand, Howard R. Levin
  • Publication number: 20190282816
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: March 28, 2019
    Publication date: September 19, 2019
    Inventors: Mark Deem, Denise Zarins, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark
  • Patent number: 10376516
    Abstract: Methods for treating a hypertensive human patient are disclosed herein. A method in accordance with one embodiment comprises delivering a neuromodulatory agent to a renal nerve of the patient via an intravascularly positioned drug delivery catheter. The method includes at least partially blocking neural activity along the renal nerve with the neuromodulatory agent, which results in a therapeutically beneficial reduction in blood pressure of the patient.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: August 13, 2019
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark Gelfand, Howard R. Levin
  • Patent number: 10376312
    Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: August 13, 2019
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Howard R. Levin, Mark Gelfand, Nicolas Zadno
  • Publication number: 20190232055
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: February 8, 2019
    Publication date: August 1, 2019
    Inventors: Mark E. Deem, Hanson Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Publication number: 20190183568
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Application
    Filed: December 5, 2018
    Publication date: June 20, 2019
    Inventors: Howard R. Levin, Mark Gelfand
  • Publication number: 20190175268
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: December 5, 2018
    Publication date: June 13, 2019
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20190175903
    Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: December 5, 2018
    Publication date: June 13, 2019
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 10300270
    Abstract: The present invention is related to an implantable medical device for treating breathing disorders and cardiac disorders by delivering stimulation energy to the phrenic nerve, hypoglossal nerves and cardiac muscle tissues.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: May 28, 2019
    Assignee: Respicardia, Inc.
    Inventors: Mark Gelfand, Howard R. Levin
  • Patent number: 10293190
    Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: May 21, 2019
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Nicolas Zadno, Benjamin J. Clark, Erik Thai, Howard R. Levin, Mark Gelfand
  • Patent number: 10272246
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: April 30, 2019
    Assignee: Medtronic Adrian Luxembourg S.a.r.l
    Inventors: Mark Deem, Denise Zarins, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark
  • Patent number: 10245429
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: April 2, 2019
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark E. Deem, Hanson Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Publication number: 20190090944
    Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.
    Type: Application
    Filed: October 5, 2018
    Publication date: March 28, 2019
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Howard R. Levin, Mark Gelfand, Nicolas Zadno
  • Patent number: 10179027
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: January 15, 2019
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 10179235
    Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: January 15, 2019
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 10179028
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: January 15, 2019
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Howard R. Levin, Mark Gelfand
  • Publication number: 20190000545
    Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues. In some embodiments, thermally-induced renal neuromodulation is achieved via delivery of a pulsed thermal therapy.
    Type: Application
    Filed: June 26, 2018
    Publication date: January 3, 2019
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Andrew Wu, Hanson Gifford, III, Mark Deem, Mark Gelfand, Howard R. Levin